Clinical Trial Update: A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 results for prasinezumab (RO7046015/PRX002) in early Parkinson's disease have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• prasinezumab (prasinezumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Parkinson's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-08